Vivos (RDGL) Free Cash Flow Growth (3y) (2013 - 2025)
Vivos (RDGL) Free Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 9.23% |
| 10 | Vivos | 22.64 Mn | 21.08 Mn | -3,105.00 | -24.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -17.45% |
| Jun 30, 2025 | -52.30% |
| Mar 31, 2025 | -5.81% |
| Dec 31, 2024 | -25.99% |
| Sep 30, 2024 | -41.66% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | -20.06% |
| Dec 31, 2023 | -8.20% |
| Sep 30, 2023 | -6.46% |
| Jun 30, 2023 | -9.55% |
| Mar 31, 2023 | -49.86% |
| Dec 31, 2022 | -3.62% |
| Sep 30, 2022 | -15.23% |
| Jun 30, 2022 | -10.37% |
| Mar 31, 2022 | -12.25% |
| Dec 31, 2021 | 23.82% |
| Sep 30, 2021 | -35.91% |
| Jun 30, 2021 | -92.62% |
| Mar 31, 2021 | -61.40% |